NTRB News and Press, Nutriband Inc. From 07/01/25

2025-07-01 07:31:34 ET More on Nutriband Nutriband issued U.S. patent for transdermal abuse deterrent technology Seeking Alpha’s Quant Rating on Nutriband Historical earnings data for Nutriband Financial information for Nutriband Read the ful...

ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), has been added as a member of the Russell Microcap, Russell Microcap Growth, Russell 3000E and Russell 3000E Growth Indexes, as part of the 2025 Russell indexes reconstitution. FTSE Russell determine...

2025-06-23 09:05:00 ET Nutriband (NASDAQ: NTRB) has received a new $15 price target in an updated report from Robert LeBoyer, Senior Vice President and Equity Research Analyst, Biotechnology, at Noble Capital Markets, following the successful completion of commercial manufacturing and s...

2025-06-20 09:50:00 ET Nutriband Inc. has been granted a new U.S. patent for its AVERSA(TM) transdermal abuse-deterrent technology, expanding its domestic IP coverage AVERSA(TM) is designed to prevent misuse, abuse, and accidental exposure of transdermal drugs with abuse potential, su...

2025-06-18 09:25:00 ET Nutriband (NASDAQ: NTRB) , a developer of prescription transdermal pharmaceutical products, announced the successful commercial manufacturing process scale-up of its lead product, Aversa Fentanyl, in collaboration with Kindeva, a global CDMO specializing in drug-d...

2025-06-18 08:45:58 ET Palm Beach, FL – June 18, 2025 – The market for abuse-deterrent opioids is still developing, but it’s estimated that replacing extended-release opioids with abuse-deterrent formulations could lead to significant cost savings and a reduction in abu...

Nutriband and Kindeva have completed commercial manufacturing process scale-up for its lead product Aversa™ Fentanyl, an abuse-deterrent fentanyl patch Nutriband is partnering with Kindeva to develop Aversa™ Fentanyl which combines Nutriband’s Aversa™ abuse-det...

2025-06-12 10:35:00 ET Financial momentum for Nutriband is indicated by its recent Q1 financial report Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report AVERSA(TM) Fentanyl has the potential to be the world’s first abuse-deterrent opi...

2025-06-09 09:05:00 ET Nutriband (NASDAQ: NTRB) has been granted U.S. patent No. 12,318,492 for its “Abuse and Misuse Deterrent Transdermal Systems,” further strengthening domestic protection for its Aversa(TM) technology. The patent, issued June 3, 2025, enhances the comp...

2025-06-09 08:21:34 ET More on Nutriband Seeking Alpha’s Quant Rating on Nutriband Historical earnings data for Nutriband Financial information for Nutriband Read the full article on Seeking Alpha For further details see: Nutriband issued U...